Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01174082 · ClinicalTrials.gov registry record · Phase 2
Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01174082: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01174082 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01174082, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if vaccinating a donor with your purified myeloma protein and then injecting it back into you will help your immune system control the multiple myeloma.
Interventions
- PROCEDURE Apheresis
- DRUG GM-CSF
- BIOLOGICAL KLH Vaccine
- BIOLOGICAL KLH-id Vaccine
- PROCEDURE Donor Lymphocyte Infusion (DLI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2010-07-20 |
| Est. Completion | 2017-02-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01174082
The ClinicalTrials.gov registry entry for NCT01174082 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Apheresis is the first listed.
NCT01174082 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01174082 about?
NCT01174082 is a clinical study titled "Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant". The goal of this clinical research study is to learn if vaccinating a donor with your purified myeloma protein and then injecting it back into you will help your immune system control the multiple myeloma.
What is the current status of trial NCT01174082?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2010-07-20. Estimated completion is 2017-02-23.
What interventions are being tested in trial NCT01174082?
The interventions under investigation include: Apheresis (PROCEDURE), GM-CSF (DRUG), KLH Vaccine (BIOLOGICAL), KLH-id Vaccine (BIOLOGICAL), Donor Lymphocyte Infusion (DLI) (PROCEDURE).
Who is sponsoring clinical trial NCT01174082?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.